Clozapine: A clinical review of adverse effects and management

Annals of Clinical Psychiatry

Volumn 15, Issue 1, 2003, Pages 33-48

  Iqbal, Mohammad Masud ^a   Rahman, Atiq ^b   Husain, Zahid ^c   Mahmud, Syed Zaber ^c   Ryan, William G ^c   Feldman, Jacqueline M ^c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adverse effects; Atypical antipsychotics; Clozapine; Conventional antipsychotics; Extrapyramidal symptoms; Neuroleptics; Schizophrenia; Side effects

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CIPROFLOXACIN; CITALOPRAM; CLOZAPINE; COCAINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; INTERFERON; KETOCONAZOLE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; QUINIDINE; RIFAMPICIN; RISPERIDONE; RITONAVIR; SERTINDOLE; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; BLOOD DYSCRASIA; BREAST FEEDING; CARDIOMYOPATHY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DELIRIUM; DEMENTIA; DIABETES MELLITUS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FETUS RISK; HUMAN; HYPERSALIVATION; LACTATION; LIVER DYSFUNCTION; MOOD DISORDER; MYOCARDITIS; MYOCLONUS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARKINSONISM; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SMOKING; TACHYCARDIA; TARDIVE DYSKINESIA; URINE INCONTINENCE; VERTIGO; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0038679586     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023228626309     Document Type: Review

References (180)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
2. Rosentein MJ, Milazzo-Sayre LJ, Manderscheid RW: Care of persons with schizophrenia: A statistical profile. Schizophr Bull 1989; 15:45-58
3. Feltus MS, Gardner DM: Second generation antipsychotics for schizophrenia. Can J Clin Pharmacology 1999; 6:187-195
4. Bartell PJ, Donenwirth K, et al.: Violence and schizophrenia: Clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995; 23:607-611
5. Cohen SA, Underwood MT: The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994; 55:440-444
6. Gilman AG, Ruddon RW, Molinoff PB, Limberd LE, Hardman JG: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Health Professions Division; 1996
7. Antipsychotic Agents: In: Baldessarini RJ, ed.: Chemotherapy in Psychiatry: Principles & Practice. Cambridge, MA: Harvard University Press, 1985:14-92
8. Hunziker F, Kunzte F, Schmutz J: Uben ein 5-Stellung basisch substituiente 5H Dibenzo (b,e)-1-4 diazepine. Helv Chim Acta 1963; 46:2337-2347
9. Hippius H: The history of clozapine. Psychopharmacology. 1989; 99:S3-S5
10. Nightingle SL: Approval of clozapine for refractory schizophrenia. JAMA 1990:263:202
11. Richelson E, Elson A: Antagonism of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984; 103:197-214
12. Waddington JL: Neuroleptic/dopamine receptors. Eur J Pharmacol 1990; 183:106
13. Meltzer HR, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of D1-D2 and serotonin, PK1 values. J Pharmacol Exp Ther 1989; 251:3238-3246
14. Picker D, Owen RR, Litran RE, Konicki PE, Gutiennez R, Rappaport HM: Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
15. 2 antagonist, augments fluphenazine in schizophrenic patients. A pilot study. J Clin Psychopharmacol 1993; 13:264-267
16. Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical antipsychotics: Part II - Adverse effects, drug interactions and costs. Ann Pharmacother 1999 33:210-217
17. Choe MG, Hsuan F, Honigfeld G, et al.: Single vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmacol Res. 1990; 7:347-351
18. Tandon R: Antipsychotic agents. In: Quitkin FM, Adams DC, Bowden CL, Heyer EJ, Rifkin A, Sellers EM, Tandon R, Taylor BP: eds. Current Psychotherapeutic Drugs, 2nd edn. Philadelphia: Current Medicine; 1998
19. Sajatovic M: Clozapine for elderly patients. Pychiatric Ann. 2000; 30(3):170-174
20. Kim BB: The Medical Letter Handbook of Adverse Drug Interactions. New York: The MedicalLetter; 2001: 206-209
21. Young CR, Bowers, MB, Jr., Mazure CM: Management of the adverse effects of clozapine. Schizophr Bull 1998; 24(3): 381-390
22. Gerson SL: G-CSF and the management of clozapine induced agranulocytosis. J Clin Psychiatry 1994; 55(Suppl B):139-142
23. Lieberman JA, Yunis J, Egen E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine induced agranulocytosis. Arch Gen Psychiatry 1990; 47:945-948
24. Alvir JM, Lieberman JA: Agranulocytosis: Incidence and risk factors. J Clin Psychiatry 1994; 55(Suppl B):137-138
25. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis - Incidence and risk factors in the United States. N Eng J Med 1993; 329:162-167
26. Lieberman JA, Kane JM, and Johns CA: Clozapine: Guidelines for clinical management. J Clin Psychiatry 1989; 50:329-338
27. Lieberman JA, Safferman AZ. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr Q 1992; 63:51-70
28. Lieberman JA: Maximizing clozapine therapy: Managing side effects. J Clin Psychiatry. 1998; 59 (Suppl 3):38-43
29. Honingfeld G, Arellano F, Sethi J, Bianchini A, Schein J: Reducing clozapine-related morbidity and mortality: 5 years experience with the Clozaril National Registry [Abstract]. J Clin Psychiatry 1998; 59(Suppl) 3:3-7
30. Silver JM, Yudofsky SC, Jurowitz GI: Psychopharmacology and electroconvulsive therapy. In: Hales RE, Yudofsky SC, Talbott JA, ed., The American Psychiatric Press Textbook of Psychiatry 2nd edn. Washington, DC. American Psychiatric Press, 1994: p. 920
31. Krupp P, Barnes P: Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology 1989; 99:S118-S121
32. Bastani B, Alphs LD, Meltzer HY. Development of the Clozaril Patinet Management System [Abstract]. Psychopharmacology 1989; 99(Suppl):S122-S125
33. Friedberg JW, Frankenburg FR, Burk J, Johnson W: Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry 1995; 7:97-98
34. Chatterton R: Eosinophilia after commencement of clozapine treatment. Aust NZ J Psychiatry 1997; 31:874-876
35. Tihonen J, Paanila J: Eosinophilia associated with clozapine. Lancet 1992; 399:488
36. Banov MD, Tohen M, Friedberg J: High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54:466- 469
37. Barbui C, Campomori A, Bonati M: Clozapine and blood dyscrasias different from agranulocytosis [Letter]. Can J Psychiatry 1997; 42(9):981-982
38. Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 1994; 55(9, Suppl B):153-156
39. Hill D: The relationship between schizophrenia and epilepsy. Folia Psychiat Neurol Neurochir 1948; 51:95-111
40. Notkin J: Epileptic manifestations in the group of schizophrenic and manic-depressive psychoses. J Nerv Ment Dis 1929; 69:494-521
41. Toth P, Frankenburg FR: Clozapine and seizures: A review. Can J Psychiatry 1994; 39:236-238
42. Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 1992; 41:369-371
43. Helwick CA: Review of clozapine therapy finds more ADRs than expected. Pharmacy Practice News 1992; March 1, p. 7
44. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
45. Claghorn J, Honigfeld G, Abuzzahab GS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
46. Schmauss M, Wolff R, Erfurth A, Ruther E: Tolerability of long term clozaril treatment. Psychopharmacology (Berl) 1989; 99:S105-S108
47. Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 1990; 147:1069-1071
48. Itil TM, Soldatos C: Epileptogenic side-effects of psychotropic drugs: Practical recommendations. JAMA 1980; 244:1460-1463
49. Karper LP, Salloway SP, Seibyl JP, et al.: Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992; 4:454-457
50. Liukkonen J, Koponen HJ, Nousiainen U: Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment. Psychiatry Res 1992; 44:107-112
51. Gouzoulis E, Grunze H, Bardeleben UV: Myoclonic epileptic seizures during clozapine treatment: A report of three cases. Eur Arch Psychiatry Neurol Sci 1991; 240:370-372
52. Gouzoulis E, Ozdaglar A, Kasper J: Myoclonic seizures followed by grand mal seizures during clozapine treatment [Letter]. Am J Psychiatry 1993; 150:1128
53. Tiihonen J, Nousiainen U, Hakola P, Leinonen E, Tuunainen A, Mervalla E, Paanila J: EEG abnormalities associated with clozapine treatment [Letter]. Am J Psychiatry 1991; 148:1406
54. Isermann H, Haupt R: Auffallige EEG-Veranderungen unter Clozapin-Behandlung bei paranoid-halluzinatorischen. Psychosen Nervenarzt 1976; 47:268
55. Baldessarini RJ, Frankenburg FR: Clozapine: A novel antipsychotic agent. New Engl J Med 1991; 324:746-754
56. Kugler J, Lorenzi E, Spatz R, et al.: Drug-induced paroxysmal EEG activities. Pharmacopsychiatry 1979; 12:165-172
57. Roubicek J, Major I: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatry 1977; 12:613-633
58. Malow BA, Reese KB, Sato S, Bogard PJ, Malhotra AK, Su TP, Pickar D: Clozapine, myoclonus, and EEG abnormalities [Abstract]. Epilepsia 1993; 34(Suppl 6):129
59. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; 99(Suppl 99):S97-S100
60. Szymanski S, Jody D, Leipsig R, Masiar S, Lieberman N: Anticholinergic delirium caused by retreatment with clozapine [Letter]. Am J Psychiatry 1992; 148:1752
61. Schuster P, Gabriel E, Kufferle B, Strobl G, Karobuth M: Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10:437-441
62. Stanilla JK, Leon J, Simpson GM: Clozapine withdrawal resulting in delirium with psychosis: A report of three cases. J Clin Psychiatry 1997; 58(6):252-255
63. Simpson GM, Varga E: Clozapine: A new antipsychotic agent. Curr Therapeut Res 1974; 16:679-686
64. Simpson GM, Lee JH, Shrivastava RK: Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56:75-80
65. Panteleeva GP, Tsutsul Kovskaya MY, Belyaev BS, et al.: Clozapine in the treatment of schizophrenic patients; An international multi-center trial. Clin Ther 1987; 10:57-68
66. Juul Povlsen U, Noring U, Fog R: Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71:176-185
67. Safferman AZ, Lieberman AJ, Kane JM: Syzmanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17(2):247-261
68. Cohen S: Sedation: In: Yesavage J, ed. Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceutical; 1992:132-133
69. Burke M, Sebastian CS: Treatment of clozapine sedation [Letter]. Am J Psychiatry 1993; 150:127
70. Meltzer HY: Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995: 631-639
71. Baker RW, Chengappa KN, Baird JW, Steingard MD, Christ MA, Schooler NR: Emergence of obsessive-compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992; 53(12):439-442
72. Levkovitch Y, Kronnenberg Y, Gaoni B: Can clozapine trigger OCD? [Letter]. J Am Acad of Child Adolesc Psychiatry 1995; 34(3):263
73. Cassidy SL, Thaker GK: Addition of fluoxetine to clozapine. Am J Psychiatry 1993; 149:1900-1901
74. Patel B, Tendon R: Development of obsessive-compulsive symptoms during clozapine treatment [Letter]. Am J Psychiatry 1993; 150(5):836
75. Tsai G, Cristomo G, Rosenblatt ML, Stern TA: Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91-95
76. Pope HG Jr, Cole JO, Choras PT Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 177(8):493-495
77. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Ann Pharmacother 1999; 33:623-630
78. Campellone JV, McCluskey LF, Greenspan D: Fatal outcome from neuroleptic malignant syndrome associated with clozapine. Neuropsychiatry Neuropsychol Behav Neurol 1995; 8:70-73
79. Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155(8):1113-1116
80. Sachdev P, Kurk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. J Clin Psychopharmacol 1995; 15(5):365-371
81. Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:717-725
82. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clinic North Am 1993; 77:185-202
83. Yamawaki S, Morio M, Kazamatsuri G, et al.: Clinical evaluation and effective usage of dantrolente sodium in neuroleptic malignant syndrome. Kiso to Rinsyou (Clinical Reports). 1993; 27:1045-1066
84. Fricchione G, Bush G, Fosdar M, et al.: Recognition and treatment of the catatonic syndrome. J Intensive Care Med 1997; 12:135-147
85. Scheftner WA, Shulman RB: Treatment choice in neuroleptic malignant syndrome. Convul Ther 1992; 8:267-279
86. Marinkovic D, Timtijevic I, Babinski T, Totic S, Paunovic VR: The side-effects of clozapine: A four year follow-up study. Prog Neuropsychopharmacol 1994; 18:537-544
87. Cohen BM, Keck PE, Satlin A, Cole JO: Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29:1215-1219
88. Safferman AZ, Lieberman JA, Pollack S, Kane JM: Akathisia and clozapine treatment [Letter]. J Clin Psychopharmacol 1993; 13:286-287
89. Wirshing WC, Phelan CK, Van Putten T, Marder SR, Engel J: Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia [Letter]. J Clin Psychopharmacol 1990; 10:371-373
90. Levin H, Chengappa KNR, Kambhamati RK, Mahdavi N, Ganguli R: Should treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53:248-251
91. Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM: Myoclonus in patients treated with clozapine: A case series. J Clin Psychiatry 1995; 56:418-422
92. Berman I, Zalma A, Durand CJ, Green AI: Clozapine-induced myoclonic jerks and drop attack [Letter]. J Clin Psychiatry 1992; 53:329-330
93. Meltzer HY, Ranjan R: Valproic acid treatment of clozapine- induced myoclonus [Letter]. Am J Psychiatry 1994; 151:1246-1247
94. Kilian JG, Kerr K, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845
95. Lilleng P, Morild I, Hope M: Clozapine and myocarditis. Tidsskr Nor Laegeforen 1995;115:293-294
96. Meeker JE, Herrmann PW, Som CW, Reynolds PC: Clozapine tissue concentrations following an apparent overdose of clozaril. J Anal Toxicol 1992; 16:54-56
97. Jensen VE, Gotzsche O: Allergic myocarditis in clozapine treatment. Ugeskr Laeger 1994; 156:4151-4152
98. Khalil N: Peri/myocarditis with clozapine (leponex). Psychiatr Prax 1997; 24:46
99. Bandelow B, Degner D, Kreusch U, Ruther E: Myocarditis under therapy with clozapine. Schizophr Res 1995; 17:293-294
100. Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997; 8:671-677
101. Leo RJ, Kreeger JL, Kim KY: Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30:603-605
102. Hagg S, Spigset O, Soderstrom TG: Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155-1156
103. Wolstein J, Grohmann R, Ruther E, Hippius H: Antipsychotic drugs and venous thromboembolism [Correspondence]. Lancet 2000; 356:252
104. Knudson JF, Kortepeter C, Debitsky GM, Ahmad SR, Chen M: Antipsychotic drugs and venous thromboemolism [Correspondence]. Lancet 2000; 356:252-253
105. Cleophas TJM, Kauw FHW: Pressor responses from noncardioselective beta-blockers. Angiology 1988; 39:587-596
106. Testani M: Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55:497-498
107. Patterson TS: In: Yesavage J, ed: Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceuticals; 1992:136-138
108. Thulesius O, Berlin E: Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. Int J Clin Ther Toxicol 1986; 24:465-467
109. Rechlin T, Claus D, Weis M: Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994; 35:888-892
110. Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: An atypical antipsychotic agent. Clin Pharmacol 1989; 8:691-709
111. Casey D: Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 (Suppl 11):40-45
112. Wetterling, T: Body weight gain with atypical antipsychotics - A comparative review. Drug Saf 2001; 24(1):59-73
113. Wirshing DA, Wirshing WC, Kysar L, Berisfor MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6):358-363
114. Bustillo JR, Buchanan RW, Irish D, Breir A: Differential effect of clozapine on weight: A controlled study. Am J Psychiatry 1996; 153(6):817-819
115. Leadbetter R, Shutty M, Pavalonis D, Vieeg V, Higgins P, Downs M: Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149(1):68-72
116. Hummer M, Kemmler G, Kurz M, et al.: Weight gain induced by clozapine. Euro Neuropsychopharmacol 1995; 5:437-440
117. Breefa D, Meehan T: Weight changes during clozapine treatment. Aust NZ J Psychiatry 1998; 32(5):718-721
118. Wetterling T, Mussigbrodt HE: Weight gain: Side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19(4): 316-321
119. Kraus T, Haack M, Schuld A, Scleh DH, Kuhn M, Uhp M, Polluacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156(2):312-314
120. George TP, Sernyak MJ, Ziedonis DM, Woods SW: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56(8):344-346
121. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997
122. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry 1994; 55(Suppl B) S157-S160
123. Willet WC, Manson JE, Stampler MJ, Colditz GA, Rosner B, Speizer FE, Hennekers CH: Weight, weight change, and coronary heart disease in women: Risk within the 'normal' weight range. JAMA 1995;273:461-465
124. Fenton WS, Blyler CF, Heinssen PK: Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 23:637-651
125. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778-783
126. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V: Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagons in the rat. Neuroendocrinology 1996; 63:269-274
127. Wozniak KM, Linnoila M: Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991; 49:101-109
128. Hayes G, Gibler B: Clozapine-induced constipation [Letter]. Am J Psychiatry 1998; 152:298
129. Lennard-Jones JE: Clinical management of constipation. Pharmacology 1993; 47:216-223
130. Bourgeois JA, Drexler KG, Hall MJ: Hypersalivation and clozapine [Letter]. Hos Comm Psychiatry 1991; 42:1174
131. Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacodynamics and pharmacokinetics of clozapine. Clinl Pharmacokinet 1993; 24:161-176
132. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW: Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997; 17(4):314-317
133. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; (Suppl 99):S97-S100
134. Kellner M, Wiedermann K, Krieg JC, Berg PA: Toxic hepatitis by clozapine treatment [Letter]. Am J Psychiatry 1993; 150:985-986
135. Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brosen K: Clozapine-induced toxic hepatitis. Ugeskrift for Laeger 2001; 163(14):2013-2014. (In Danish)
136. Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR: Hepatitis, hyperglycemia, pleural effesion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13(2):95-98
137. Dystonia and drug-induced hepatitis in a patient treated with clozapine [Letter]. Am J Psychiatry 1995; 152(4):647-648
138. Thatcher GW, Cates M, Bair B: Clozaine-induced toxic hepatitis [Letter]. Am J Psychiatry 1995; 152(2):296-297
139. Sepulveda VAC, Lopez AE, Yanez LP, Ramirez CR, Escobar PB, Madrazo DGA: Sodium diphenylhydantoin as a probable cause of pancreatitis. Rev Gastroenterol Mex 1999; 64(4):186-189. (In Spanish)
140. Bergemann N, Ehrig C, Diebold K, Mundt C, von Einsiedel R: Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32(2):78-80
141. Jubert P: Clozapine-related pancreatitis [Letter]. Ann Intern Med 1994; 121(9):722-723
142. Martin A: Acute pancreatitis associated with clozapine use [Letter]. Am J Psychiatry 1992; 149:714
143. Frankenburg FR, Kando J: Eosinophilia, clozapine and pancreatitis [Letter]. Lancet 1992; 340:251
144. Davydov Liya, Botts SR: Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34:662-665
145. Robinson D, Fenn H, Yesavage J: Possible association of parotitis with clozapine. Am J Psychiatry 1995; 152:297-298
146. Brodkin ES, Pelton GH, Price LH: Treatment of clozapine-induced parotid gland swelling [Letter]. Am J Psychiatry 1996; 153:445
147. Vasile JS, Steingard S: Clozapine and the development of salivary gland swelling: A case study. J Clin Psychiatry 1995; 56:511-513
148. Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M: Aspiration pneumonia possibly secondary to clonzapine-induced sialorrhea [Letter]. J Clin Psychopharmacol 1996; 16:462-463
149. 4 receptor agonist. Eur J Pharmacol 1994; 269:R1-R2
150. Szabadi E: Clozapine-induced hypersalivation [Letter]. Br J Psychiatry. 1997; 171:89
151. 2-adrenoceptor antagonist therapy. Trends Pharmocol Sci 1992; 13:277-282
152. Pearlmen C. Clozapine, nocturnal sialorrhea, and chocking [Letter]. J Clin Psychopharmacol 1992; 12:69-70
153. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A: Trihexiphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmocol 1997; 12:213-215
154. Copp PJ, Lament R, Tennent TG: Amitriptyline in clozapine- induced sialorrhea [Letter]. Br J Psychiatry 1991; 159:166
155. Grabowski J: Clonidine treatment of clozapine-induced hypersalivation [Letter]. J Clin Psychopharmacol 1992; 12:69-70
156. 2-adrenoceptor [Letter]. Br J Psychiatry 1995; 167:412
157. Aronowitz JS, Safferman AZ, Lieberman JA: Management of clozapine induced enuresis [Letter]. Am J Psychiatry 1995; 152:472
158. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE: Clozapine-induced urinary incontinence: Incidence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514-518
159. Steingard S: Use of desmopressin to treat clozapine-induced enuresis [Letter]. J Clin Psychiatry 1994; 55:325-326
160. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med 1985; 103:228-239
161. Frankenburg FR, Kando JC, Centorrino F, Gilbert JM: Bladder dysfunction associated with clozapine therapy. J Clin Psychiatry 1996; 57:39-40
162. Renwick AC, Renwick AG, Flanagan RJ, Ferner RE: Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. Clin Toxicol 2000; 38(3):325-328
163. Meeker JE, Herrmann PW, Som CW, Reynolds PC: Clozapine tissue concentrations following apparent suicidal overdose of clozaril. J Anal Toxicol 1992; 16:54-56
164. Worm K, Birgitte K, Steentoft A: Clozapine cases with fatal, toxic or therapeutic concentrations. Int J Legal Med 1993; 106:115-118
165. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J: Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112:1707-1709
166. Panagiotis B: Grand mal seizures with liver toxicity in a case of clozapine treatment [Letter]. J Neuropsychiatry Clin Neurosci 1999; 11(1):117-118
167. Schuster P, Gabriel E, Kufferle B, Strobl G, Karobath M: Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10(4):437-441
168. Ishii A, Mizoguchi K, Kageoka M, Seno H, Kumazawa T, Suzuki O: Nonfatal suicidal intoxication by clozapine. Clin Toxicol 1997; 35(2):195-197
169. Mady S, Wax P, Wang D, Goetz C, Hadley C, Love R: Pediatric clozapine intoxication. Am J Emerg Med 1996; 14:462-463
170. USP DI Drug Information for the Health care professional, Vol 1, 18th edn. Rockville, MD: United States Pharmacopeial Convention; 1998
171. Physician's desk reference, 53rd edn. Montvale, NJ: Medical Economics; 1999
172. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW: Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151(6):945
173. Waldman MD, Safferman AZ: Pregnancy and clozapine. Am J Psychiatry 1993; 150(1):168-169
174. Lieberman J, Safferman AZ: Clinical profile of clozapine: Adverse reactions and granulocytosis, in clozapine in treatment resistant schizophernia. A Scientific Update. Am J Psychiatry. 1993; 150(1):168-169
175. Rice DP, Miller LS: The economic burden of schizophernia. Conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius, eds. schizophernia, Vol 1, Handbook of Mental Health Economics and Health Policy. New York: Wiley; 1996: 321-334
176. Nightangle SA: Approval of clozapine for refractory schizophernia, JAMA 1990; 263:202
177. Zito JM: Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clin North Am 1998; (21):181-202
178. Zito JM, Provenzaro G: Pharmaceutical decision making: Pharmaco epidemiology or pharmacoeconomics - Who's in the driver's seat? Psychopharmacol Bull 1996; 31:735-744
179. Revick DA, Luce BR, Weschler JM, Browns RE, Adler MA: Cost effectiveness of clozapine for treatment resistant schizophernia patients: Hosp Community Psychiatry 1990; 41:850-854
180. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patient with refractory schizophernia outcome and cost. N Eng J Med 1997; 337:809-815